Navigation Links
Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
Date:10/26/2009

SAN DIEGO, Oct. 26 /PRNewswire/ -- Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

The Company's flu program has identified a compound, IkT-041, comparable in activity to viral neuraminidase inhibitors (e.g. Tamiflu, Relenza), but one that is far less likely to stimulate resistance. IkT-041 has excellent human dosing metrics (up to 3000 mg/day), outstanding safety history in humans and an oral bioavailability > 70%.

The Company's orphan drug program is focused on satisfying an unmet medical need for the treatment of polyomavirus infections. The human polyomaviruses, JC and BK, are responsible for fatal disorders of the brain and kidney, to include progressive multifocal leukoencephalopathy (PML), an AIDS-defining disease that also afflicts patients on autoimmune disorder treatments for MS, lupus and arthritis. IkT-001 has a mechanism of action that can suppress polyomavirus reactivation in viral reservoirs, even in patients who are immune compromised. In some cases, a therapeutic vaccine effect can be realized with this product.

The Company is on track to file 3 Initial New Drug applications in 2010 or early 2011 and enter late stage clinical trials shortly thereafter. First product launch is slated for 2013, addressing a total market of greater than 100 million patients with annual revenue potential of at least $2.3 billion.

SOURCE Inhibikase Therapeutics


'/>"/>
SOURCE Inhibikase Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual BIO Investor Forum
2. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
3. Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
4. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
5. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
6. ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
7. Prime Therapeutics Receives 2010 TIPPS Certification for Adherence to High Transparency Standards
8. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
9. Solace Therapeutics, Inc. Announces CE Mark Approval
10. Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference
11. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... , , ... 2009 Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced ... trial in patients chronically infected with the hepatitis C virus (HCV). The ... antiviral effect of clemizole monotherapy in the absence of interferon. ...
... , , LYON, France ... the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and ... submitted to the U.S. Food and Drug Administration (FDA) a ... vaccine. Responding to recent recommendations by the FDA, the company,s ...
Cached Medicine Technology:Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial 2Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial 3Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA 2Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA 3
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, ... Health Alliance (PPHA). The PPHA's passion for others' well-being ... NFL greats, treated for obstructive sleep apnea (OSA) has propelled ... cause in the valley. The most recent plans for an ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... Jude scientist honored , , MEMPHIS, Tenn., June 16 ... in the Pathology Department at St. Jude Children,s Research Hospital, ... Sciences. , , Selected by The Pew Charitable Trusts ... scientists, Mullighan will receive a $240,000 award over four years ...
... , NIXA, Mo., June 16 The National Autism Association ... charge to qualifying couples who have a child with autism. ... divorce within the autism community, the NAA,s Family First Program ... need of marriage counseling. Now the organization is providing tools ...
... -- Duke University engineers have taken a first ... by combining chemotherapy with heat administered from the end ... it should be technically possible to treat brain tumors ... of surgery, systemic chemotherapy or radiation. The bioengineers ...
... and the Association of Medicine and the Person are collaborating ... . The peer-reviewed, international journal is aimed at medical ... field of ethics and quality of life. The first ... The Journal of Medicine and the Person ...
... of organizations representing healthcare stakeholders throughout Greater Boston ... Foundation (RWJF) to participate in a planning grant ... Quality (AF4Q) initiative. AF4Q is the Foundation,s signature ... in targeted communities, reduce racial and ethnic disparities, ...
... ... ... , , ,Who: ,Dr. Jeffrey Sturchio, Chairman, Corporate Council on Africa, ... Office of the U.S. Global AIDS Coordinator, U.S. Department of State ,Dr. Kate Tulenko, ...
Cached Medicine News:Health News:St. Jude Scientist Named Pew Scholar 2Health News:St. Jude Scientist Named Pew Scholar 3Health News:National Autism Association's Family First Program Now Providing Free Tools to Help Combat Autism Divorce Rates 2Health News:Potential for noninvasive brain tumor treatment 2Health News:Springer to publish Journal of Medicine and the Person 2Health News:Greater Boston unites to transform health care 2Health News:Building Healthcare Leadership in Africa: A Call to Action 2
Angulated, blunt and pointed tips....
Bipolar hand activated forceps....
Angled, pointed, with attached cable for Valleylab and other brands generators....
Angulated, blunt tips....
Medicine Products: